Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications
BEDMINSTER, N.J. and DUBLIN, Ireland , June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted
View HTML
Toggle Summary Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland , June 07, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific
View HTML
Toggle Summary Amarin Announces Patent Litigation Settlement Agreement with Teva
BEDMINSTER, N.J. and DUBLIN, Ireland , May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with Teva
View HTML
Toggle Summary Amarin to Present at the Jefferies Global Healthcare Conference
BEDMINSTER, N.J. , and DUBLIN, Ireland , May 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations
REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. and DUBLIN, Ireland , May 02, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the
View HTML
Toggle Summary Amarin To Report First Quarter 2018 Results and Host Conference Call On May 2, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland , April 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with
View HTML
Toggle Summary Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer
BEDMINSTER, N.J. , and DUBLIN, Ireland , April 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, today announced that Aaron Berg has been promoted to
View HTML
Toggle Summary Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions
BEDMINSTER, N.J. and DUBLIN, Ireland , April 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health,  is supporting the presentation of three accepted scientific
View HTML
Toggle Summary Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides
BEDMINSTER, N.J. and DUBLIN, Ireland , April 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the presentation of two posters this week at
View HTML
Toggle Summary Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa® Promotion Initiatives
Over 97% of Final Patient Visits in REDUCE-IT Completed or Scheduled for Near-Term Completion
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation